CHADD is part of a social movement that seeks to shape the conversation on how society treats, accommodates, and views people affected by ADHD. Our movement is made up of countless people affected by ADHD, their families, teachers, friends, and leaders in the fields of ADHD research, education, and mental health. We realize the most effective way to accomplish our goals is through sustained and strategic outreach to policymakers on the state and federal levels.
We are making a difference for for families and adults affected ADHD. And we need your help! We want you to be equipped with information to make a difference in your own life, whether that means dealing with issues in the classroom, the boardroom, or your living room.
PUBLIC POLICY POSITIONS
The US Food and Drug Administration recently asked for comments on making stimulant medications more difficult to abuse and how those changes could affect the millions of people who include medication in their ADHD treatment plans. The Federal Register notice states that stimulant medications can be open to abuse but that reformulating them can potentially…
At eight years old, Michael was diagnosed with ADHD. The traditional city school he attended declined to evaluate him to determine eligibility for special education and related services because his grades were above average. Instead, the school provided Michael with minimal accommodations through a 504 plan. As the years progressed, Michael’s grades began to decline,…
CHADD and Russell A. Barkley, Ph.D., Partner Announce New Findings Lanham, Md. (Jan. 8, 2019)— The message is clear. Treatment for attention-deficit/hyperactivity disorder (ADHD), along with the related health risks it poses, has the possibility of adding an average of nine to 13 years to the lifespan of children and adults diagnosed with ADHD.…
CHADD has become aware of state and local policies, including legislation and regulations, intended to address the misuse of opioids, but which may have unintended consequences for children and adults prescribed FDA-approved medications to treat attention deficit hyperactivity disorder (ADHD). Read the full statement.
Medication Access Principles: CHADD ascribes to the following principles regarding access to medications indicated to treat attention deficit / hyperactivity disorder (ADHD). Medication is recognized by the scientific community as a primary treatment to effectively reduce the core symptoms of ADHD. Given the stigma associated with ADHD and common misconceptions about treating the disorder, individuals…
The House of Representatives had been preparing to vote on the American Health Care Act (AHCA), which would repeal significant portions of the Affordable Care Act (ACA or “Obamacare”) and replace them with alternative coverage policies. At this time, the House is not moving forward with a vote on the AHCA. Read our full report.
In September 2016, CHADD conducted a survey about health insurance coverage and attention deficit hyperactivity disorder (ADHD) in the United States. More than 1500 people from all 50 states and Washington, D.C. took part in the online survey and answered 15 anonymous questions about their personal experiences seeking access to services and medications for their,…
- CDC-National Center Birth Defects & Developmental Disabilities External Partners Group
- Consortium for Citizens with Disabilities
- Mental Health Liaison Group
- IDEA Partnership
- Bazelon Center for Mental Health Law
- Alliance to Prevent Restraint, Aversive Intervention & Seclusion
- American Academy of Child and Adolescent Psychiatry
- National Alliance on Mental Illness
- Mental Health America